All In Biotech

Drug Trial Radar · NCT05101187

Olorofim Aspergillus Infection Study

Phase III, Adjudicator-blinded, Randomised Study to Evaluate Efficacy and Safety of Treatment With Olorofim Versus Treatment With AmBisome® Followed by Standard of Care in Patients With Invasive Fungal Disease Caused by Aspergillus Species

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

Apr 29, 2022

Primary completion

Nov 18, 2025

Study completion Mar 19, 2026

Sponsor

Lead sponsor
F2G LtdIndustry
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd; Shionogi
First posted
Nov 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).

Conditions

  • Invasive Aspergillosis

Interventions

  • OlorofimDrug

    Loading Dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 Maintenance Dose: 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 84 (± 7 days)

  • AmBisome®Drug

    Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortalityTime frame: Treatment Day 42

Locations

143 sites in 21 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • City of Hope National Medical Center

    Duarte, California

  • University of California Davis Health System

    Sacramento, California

  • UCSF Helen Diller Medical Center at Parnassus Heights

    San Francisco, California

  • University of Florida

    Gainesville, Florida

  • Augusta University

    Augusta, Georgia

  • University of Chicago Medical Center

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • The Johns Hopkins Hospital

    Baltimore, Maryland

  • NIH Clinical Center ,NIAID,NIH

    Bethesda, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Clairvoyant Research Group, LLC

    Las Vegas, Nevada

  • Rutgers RWJMS

    New Brunswick, New Jersey

  • Weill Cornell Medicine NY Presbyterian Hospital

    New York, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Duke Department of Medicine Infectious Diseases Division

    Durham, North Carolina

  • OU Health OU Medical Center

    Oklahoma City, Oklahoma

  • University of Pittsburgh Medical Center Health System

    Pittsburgh, Pennsylvania

  • Houston Methodist

    Houston, Texas

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Royal NorthShore Hospital

    Saint Leonards, New South Wales, Australia

  • Royal Brisbane & Women's Hospital

    Herston, Queensland, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • AZ Sint-Jan

    Bruges, Belgium

  • Hôpital Erasme

    Brussels, Belgium

  • UZ Leuven

    Leuven, Belgium, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Gent, Belgium

  • Hospital Felício Rocho

    Belo Horizonte, Minas Gerais, Brazil

  • Santa Casa de Misericórdia de Belo Horizonte

    Belo Horizonte, Minas Gerais, Brazil

  • Santa Casa de Misericórdia de Passos

    Passos, Minas Gerais, Brazil

  • Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer

    Curitiba, Paraná, Brazil

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital São Lucas da PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

Showing 40 of 143 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.